Table 1

Baseline characteristics for the patients with OJIA and PJIA starting their first MTX

OJIAPJIA
Patient characteristics
  N3974
 Sex, female (%)31 (79)53 (72)
 Median age at onset (year) (IQR)4.5 (1.9–8.5)7.5 (4.3–11.8)
 Median disease duration (year) (IQR)0.8 (0.3–1.9)0.5 (0.2–1.1)
 ANA+ (%)16 (41)33 (45)
 Rheumatoid factor+ (%)0 (0)5 (8)
 HLA-B27+ (%)4 (25)6 (16)
Subtype of JIA
 Oligoarticular (%)39 (100)19 (26)
  Persistent (%)38 (97)
  Extended (%)19 (26)
 Polyarticular RF− (%)48 (65)
 Polyarticular RF+ (%)6 (8)
 Psoriatic arthritis (%)1 (1)
 Undifferentiated arthritis (%)1 (2.6)
Disease activity at baseline
 Median parent/patient VAS (IQR)45 (8-65)46 (25-70)
 Median PGA (IQR)20 (15-35)30 (20-41)
 Median number of active joints (IQR)2 (1-3)6.0 (3.0–9.3)
 Median cJADAS (IQR)8.0 (4.0–10.0)14.5 (10.1–20.0)
 Uveitis present (%)0 (0)1 (1)
Comedication at start MTX
 IA steroids (%)6 (15)10 (14)
 Prednisolon (%)1 (3)9 (12)
  • ANA, antinuclear antibody; cJADAS, clinical juvenile arthritis disease activity score; HLA, human leucocyte antigen; IA, intra-articular; JIA, juvenile idiopathic arthritis; MTX, methotrexate; OJIA, oligoarticular JIA; PGA, physician’s global assessment; PJIA, polyarticular course JIA; RF, rheumatoid factor; VAS, Visual Analogue Scale.